New Study Addressing Global Concern for Breast Cancer Treatment Now Available in Clifton, N.J.

A cancer research study focusing on hormone receptor-positive HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) is now available to patients in the Clifton, N.J., area.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Monday, March 4, 2024
Information
Tags: 
Research, Pharmaceutical, Oncology, Consumer, Hospitals, Genetics, Clinical Trials, Science, Women, Seniors, FDA, Practice Management, Health, Quality of life, AstraZeneca, MBC, Mutation, ESR1, Patient, Birth control
Geotags: 
UNITED STATES, NORTH AMERICA, MASSACHUSETTS, NEW JERSEY
Organisation: 
CARE ACCESS
Summary
Key Points: 
  • A cancer research study focusing on hormone receptor-positive HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) is now available to patients in the Clifton, N.J., area.
  • The SERENA-6 trial, sponsored by AstraZeneca, is a global study that aims to address a critical issue faced by many patients: their treatments become less effective over time.
  • In advanced breast cancer, patients receive a treatment that combines an estrogen-reducing drug with a drug that slows cancer cell growth.
  • This study will evaluate if an experimental trial drug, combined with a cancer-slowing drug, might work better than conventional estrogen-reducing drugs for patients with ESR1 mutations.


A cancer research study focusing on hormone receptor-positive HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) is now available to patients in the Clifton, N.J., area.

The SERENA-6 trial, sponsored by AstraZeneca, is a global study that aims to address a critical issue faced by many patients: their treatments become less effective over time.

In advanced breast cancer, patients receive a treatment that combines an estrogen-reducing drug with a drug that slows cancer cell growth. While this combination works well, over time, it may stop working because of mutations in the ESR1 gene. This study will evaluate if an experimental trial drug, combined with a cancer-slowing drug, might work better than conventional estrogen-reducing drugs for patients with ESR1 mutations.

“The goal of this trial is to help participants stay on their treatment plan for as long as possible, delaying the need for more intensive therapies like chemotherapy, which can be hard on the body,” said Dr. Richards Afonja, Principal Investigator at Care Access - Clifton. “Ultimately, we hope to improve the quality of life for patients.”

Participants in this phase 3 study must have been diagnosed with HR+/HER2-MBC and have an ESR1 mutation. To learn more, visit careaccess.com/studies or contact Care Access at (351) 222-5112.

Care Access opened its Clifton, N.J., location in collaboration with local community leaders and healthcare providers seeking to make clinical research more accessible to the greater Clifton community.

About Care Access

Care Access is a global clinical research company helping to accelerate the future of medicine. With a global network of over 200 research sites, Care Access supports research studies conducted by 14 of the top 15 biopharmaceutical companies. In addition to its proven track record of globally top-enrolling sites, Care Access partners with new-to-research communities and establishes high-quality research site infrastructure locally to expand access to clinical trials and increase representation.

For research sponsors, Care Access offers three core services: (1) global network of research sites, (2) community screenings to expand a study’s reach, and (3) on-demand staffing, space expansion, and training services to support all research sites on a study.

To learn more about active studies at Care Access, or how Care Access helps sponsors achieve enrollment and representation goals, visit www.careaccess.com.

Copyright: 
Copyright Business Wire 2024